Australian Institute of Health and Welfare (AIHW) 2002,Health Expenditure in Australia
2001, Canberra.

Australian Institute of Health and Welfare (AIHW) 2003, Health Expenditure in Australia
2002, Canberra.

Catalan, V. S. and LeLorier, J. 2000,Predictors of Long-term Persistence on Statins in a
Subsidised Clinical Population, Value in Health , vol. 3, pp. 417-426.

Commonwealth of Australia 2002, Intergenerational Report 2002-03, Budget Paper no. 5,
Canberra.

Corbett, J. 2003, Because it Matters, Big Time, paper presented paper presented at the
conference.The Future of the Pharmaceutical Benefits Scheme: Sustaining and Improving
Australians Access to Quality Medicines, PBS, Sydney, 11-12 September.Datamonitor 2002,The New Generation Blockbusters, May, 6 & 26.

George, B., Harris, A. and Mitchell, A. 1998,Reimbursement Decisions and the Implied Value
of Life: Cost effectiveness analysis and decisions to reimburse pharmaceuticals in Australia
1993,in Harris, A. (ed), Economics and Health: Proceedings of the 19th Australian
Conference of Health Economics, University of New South Wales, Sydney, pp. 1-17.


Houghton, J.W. 2003, Australian ICT Industries Update 2003, sponsored by the Australian
Computing Society, Centre for Strategic Economic Studies, Victoria University, Melbourne.
IBM Global Services (IBMGS) 2002, Pharma 2010: The Threshold of Innovation, available at
http://www-1.ibm.com/services/strategy/e_strategy/pharma_2010.html
Lazarou, J., Pomeranz, B. et al. 1998,Incidence of adverse drug reactions in hospitalised
patients: A meta-analysis of prospective,JAMA, vol. 279, no. 15, pp. 1200-1205.

Lichtenberg, F. 1996,Do (more and better) drugs keep people out of hospitals?, American
Economic Review, vol.86, no. 2, pp. 384-389.

Lichtenberg, F. 2003,The Impact of New Drug Launches on Longevity: Evidence from
Longitudinal, Disease Level Data from 52 Countries, 1981-2001, NBER Working Paper
no. 9754, NBER, Cambridge, Mass.

Market Letter: The Authoritative Newsletter for the World Health Care Industry 1999, Noncompliance
costs almost $100 billion pa, IMS World Publications, London, 21 June.

McGavock, H. 1996, A Review of the Literature on Drug Adherence, Royal Pharmaceutical
Society of Great Britain, London.

Nordhaus, W. 1999,The Health of Nations: The Contribution of Improved Health Standards,
paper presented at the conference,Economic Returns of Medical Research, Lasker/Funding
first, at http://www.laskerfoundation.org/reports/reports.html

Sweeny, K. 2003,Price and Quantity Trends in the Pharmaceutical Benefits Scheme,Pharmaceutical Industry Project Draft Working Paper, Centre for Strategic Economic
Studies, Melbourne.

Wanless, D. 2002, Securing our Future Health: Taking a Long-Term View, HM Treasury,
London, available at http://www.hmtreasury.
gov.uk/consultations_and_legislation/wanless/consult_wanless_interimrep.cfm